Testing a new naltrexone implant for treating methamphetamine use disorder.
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).
This study is looking at a new long-lasting implant that delivers medication to help people with Methamphetamine Use Disorder stay off meth, either on its own or with another medication, to see how well it works and if it's safe for you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biocorrx Pharmaceuticals INC NIH-funded |
| Lab location | 1 site (Anaheim, United States) |
| Project ID | NIH-11042242 on NIH RePORTER |
What this research studies
This research investigates the use of BICX104, a long-lasting naltrexone implant, either alone or combined with bupropion, to treat individuals with Methamphetamine Use Disorder (MUD). The study aims to evaluate the safety and effectiveness of this treatment approach, which could help maintain abstinence from methamphetamine use. By using a subcutaneous implant, the research seeks to improve patient compliance compared to traditional oral medications, ensuring consistent therapeutic levels of the drug. Participants will be compared against a placebo group to assess the benefits of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Methamphetamine Use Disorder who are seeking treatment.
Not a fit: Patients who are not diagnosed with Methamphetamine Use Disorder or those who are currently using other forms of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with methamphetamine addiction.
How similar studies have performed: Previous studies have shown promise in using naltrexone for substance use disorders, but this specific approach with BICX104 is novel.
Where this research is happening
Anaheim, United States
- Biocorrx Pharmaceuticals INC — Anaheim, United States (Active)
Researchers
- Principal investigator: Beebe Devarney, Katherine — Biocorrx Pharmaceuticals INC
- Study coordinator: Beebe Devarney, Katherine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.